Abstract
Systemic treatment for patients (pts) with BRAF- mutated (mut) melanoma (mel) and brain metastasis (BMs) include immunotherapy and targeted therapy. COMBI-MB clinical trial analyzed the role of dabrafenib + trametinib, with an intracranial response rate (icRR) of 58% for asymptomatic and 59% for symptomatic pts. Encorafenib + binimetinib (EB) has not been prospectively evaluated in this scenario.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
